Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2/3 Age De-escalating Study to Evaluate the Safety and Immunogenicity of a SARS-CoV-2 Recombinant Spike Protein Vaccine (SARS-CoV-2 rS) With Matrix-M™ Adjuvant in Children 6 Months to < 12 Years of Age

NCT05468736 is registered in ClinicalTrials.gov with Novavax as lead sponsor.

NCT NCT05468736
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05468736 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2/3 Age De-escalating Study to Evaluate the Safety and Immunogenicity of a SARS-CoV-2 Recombinant Spike Protein Vaccine (SARS-CoV-2 rS) With Matrix-M™ Adjuvant in Children 6 Months to < 12 Years of Age
Lead sponsor
Novavax
Phase
Phase 2/3
Overall status
Completed
Start date
July 22, 2022
Completion date
October 25, 2025
Enrollment
3,600 (actual)
Sites
94

Conditions

As the registry lists them; a condition with its own page is linked.

covid-19